Featured Research

from universities, journals, and other organizations

Eplerenone reduces primary endpoint in acute myocardial infarction patients

Date:
April 29, 2014
Source:
European Society of Cardiology (ESC)
Summary:
A drug known to reduce mortality rate in patients with heart failure has now been found significantly effective when administered early in patients following an acute (ST elevated) myocardial infarction. This effect, say the investigators, was consistent across all study sub-groups, but was "particularly obvious in patients undergoing reperfusion within six hours of symptom onset".

A drug known to reduce mortality rate in patients with heart failure has now been found significantly effective when administered early in patients following an acute (ST elevated) myocardial infarction. This effect,say the investigators, was consistent across all study sub-groups, but was "particularly obvious in patients undergoing reperfusion within six hours of symptom onset."

Eplerenone, a mineralocorticoid receptor antagonist (MRA), has already been investigated and licensed for the use in patients with heart failure post myocardial infarction, but has so far not been investigated following acute STEMI without ongoing heart failure. Such a study, said principal investigator Gilles Montalescot from the Institut de Cardiologie, Pitié-Salpêtrière University Hospital in Paris, would be "a valuable venture both because of the potentially beneficial effects and a proof of safety in the acute phase of MI."

The study was a multicentre placebo-controlled trial in which 1012 acute STEMI patients with no history of heart failure were randomised to either eplerenone (25/50 mg per day) or placebo, initiated within 24 hours of the onset of symptoms and in addition to standard therapy. The primary endpoint of the study was a composite of cardiovascular mortality, re-hospitalisation or extended initial hospital stay as a result of diagnosed heart failure, sustained ventricular tachycardia or fibrillation, and clear signs of heart fialure (ejection fraction ≤40%, or elevated levels of BNP/NT-proBNP [two similar cardiac peptides whose release can be measured as a biomarker of heart failure]).

Results of the study, with an accompanying editorial, are reported today in the European Heart Journal.

After a mean follow-up of 10.5 months, the primary endpoint occurred in 93 patients in the eplerenone group (18.4%) and in 150 patients in the placebo group (29.6%). This difference was statistically significant (adjusted hazard ratio 0.57, 95% CI 0.44-0.74, P<0.0001).

However, the investigators found that this primary endpoint difference was largely driven by changes in levels of BNP/NT-proBNP, with lower overall levels in the treatment group (BNP and NT-pro-BNP levels in blood increase when heart failure symptoms worsen). This difference in levels of BNP and Nt-proBNP was statistically significant. But there was no significant difference in any other components of the primary endpoint -- though the investigators point out that cardiovascular event rates in this study were too small to show statistically significant change. More than 10,000 patients in each arm would have been necessary to demonstrate a 15-20% event reduction -- which is why biomarkers rather than hard clinical endpoints drove the significant outcome.

As background to their report, the authors note that eplerenone has been shown to reduce mortality in patients with heart failure, particularly in those following recent MI. In the EPHESUS trial, for example, eplerenone was more effective with early (3-7 days post MI) administration than with later (7-14 days). However, despite these results (and consequent guideline recommendations), the authors note that the use of eplerenone in post-MI populations has remained low, partly because of safety concerns about hyperkalaemia. However, in this study the adverse event rates were similar in both groups, with serum potassium levels above 5.5mmol/L in 5.6% and 3.2% in the eplerenone and placebo groups, respectively, a non-significant difference. The authors described eplerenone in this study as "safe" and "generally well tolerated."

Commenting on the results, Professor Montalescot said: "This study suggests that eplerenone can be used early in the course of MI without safety issues. The long term benefit on remodelling and secondary heart failure is possible but will deserve further studies."


Story Source:

The above story is based on materials provided by European Society of Cardiology (ESC). Note: Materials may be edited for content and length.


Journal Reference:

  1. G. Montalescot, B. Pitt, E. Lopez de Sa, C. W. Hamm, M. Flather, F. Verheugt, H. Shi, E. Turgonyi, M. Orri, J. Vincent, F. Zannad, G. Noll, R. Weir, B. O'Neill, M. Bohm, W. S. Hillis, A. Grieve, J.-L. Rouleau, F. Gerasimos, D. Fitchett, S. Lepage, M. Madan, B. Sussex, G. Tremblay, R. Welsh, G. Wong, M. Hutyra, J. Kettner, P. Ostadal, J. Spinar, J. Vojacek, M. Barboteu, J.-P. Collet, P. Coste, Y. Cottin, D. Ducos, M. Galinier, E. Teiger, G. Zemour, J. Bauersachs, R. Hambrecht, G. Hauf, H. Heuer, H. Mudra, T. Munzel, S. Steiner, R. Strasser, K. Sydow, C. Tschope, R. Wachter, N. Werner, D. Alexopoulos, D. Babalis, V. Pyrgakis, C. Dezsi, G. Lupkovics, P. Polgar, J. Tomcsanyi, J. Herrman, J. M. ten Berg, J. Gorny, J. Kubica, J. Lewczuk, W. Zmuda, M. Hranai, F. Kovar, R. Margoczy, K. Micko, J. Sumbal, X. B. Genover, A. F. Ortiz, M. F. Sala, C. G. Garcia, C. P. Munoz, J. R. Rey Blas, F. R. Soriano, D. Adamson, F. Alamgir, A. Chauhan, G. Lip, T. Martin, G. McCann, D. Newby, D. Smith. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. European Heart Journal, 2014; DOI: 10.1093/eurheartj/ehu164

Cite This Page:

European Society of Cardiology (ESC). "Eplerenone reduces primary endpoint in acute myocardial infarction patients." ScienceDaily. ScienceDaily, 29 April 2014. <www.sciencedaily.com/releases/2014/04/140429205731.htm>.
European Society of Cardiology (ESC). (2014, April 29). Eplerenone reduces primary endpoint in acute myocardial infarction patients. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2014/04/140429205731.htm
European Society of Cardiology (ESC). "Eplerenone reduces primary endpoint in acute myocardial infarction patients." ScienceDaily. www.sciencedaily.com/releases/2014/04/140429205731.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com
Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins